Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with temozolomide and radiotherapy within its marketing authorisation for newly diagnosed MGMT-methylated glioblastoma multiforme.
 
Status In progress
Process STA 2018
ID number 1582

Provisional Schedule

Expected publication 26 August 2020

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 September 2019 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation. Please note that following on from advice received from the company the timelines for this appraisal are currently to be confirmed. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.
28 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.
08 May 2019 - 06 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 April 2018 In progress, DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance